the vision to heal

The potential to simulate natural healing


Noveome is advancing its ST266 platform biologic, a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. We believe this novel platform biologic holds significant clinical potential across a range of important underserved conditions in ophthalmology, neurology, dermatology—and beyond.

exciting science

Learn more about ST266 and its unique and powerful healing potential.

advancing pipeline

Explore our portfolio covering a range of important ophthalmic indications.

rewarding careers

Join a passionate, diverse team dedicated to making a positive difference in patients’ lives.

making news

June 23, 2021

Noveome Biotherapeutics, Inc. Commences Phase 1 Clinical Study of ST266…

June 7, 2021

Noveome Biotherapeutics, Inc. Announces Preliminary Results of its Phase 1…

June 1, 2021

Noveome Biotherapeutics, Inc. and SipNose, Ltd. Announce Commercial License Agreement…